Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?

Hormone receptor-positive (HR-positive), HER2-negative breast cancers comprise the majority of breast cancer diagnoses and display wide variation in recurrence risk.1 The adjuvant use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) can reduce recurrences in higher-risk HR-positive tumors with axillary lymph node involvement and/or biologically aggressive features.2,3 In adjuvant trials, the monarchE (abemaciclib) and NATALEE (ribociclib) studies demonstrated improved invasive disease-free survival…